Vasoactive therapy in systemic sclerosis: Real-life therapeutic practice in more than 3000 patients

Journal of Rheumatology

Volumn 43, Issue 1, 2016, Pages 66-74

  Moinzadeh, Pia ^a   Riemekasten, Gabriela ^c   Siegert, Elise ^d   Fierlbeck, Gerhard ^f   Henes, Joerg ^f   Blank, Norbert ^g   Melchers, Inga ⁱ   Mueller Ladner, Ulf ^j   Frerix, Marc ^j   Kreuter, Alexander ^k   Tigges, Christian ^k   Lahner, Nina ^l   Susok, Laura ^l   Guenther, Claudia ^m   Zeidler, Gabriele ⁿ   Pfeiffer, Christiane ^o   Worm, Margitta ^d   Karrer, Sigrid ^p   Aberer, Elisabeth ^aj   Bretterklieber, Agnes ^aj   Genth, Ekkehard ^q   Simon, Jan C ^r   Distler, Joerg H W ^s   Hein, Ruediger ^t   Schneider, Matthias ^v   Seitz, Cornelia S ^w   Herink, Claudia ^w   Steinbrink, Kerstin ^x   Sárdy, Miklos ^u   Varga, Rita ^u   Mensing, Hartwig ^y   Mensing, Christian ^y   Lehmann, Percy ^z   Neeck, Gunther ^aa   Fiehn, Christoph ^ab   Weber, Manfred ^b   Goebeler, Matthias ^ac   Burkhardt, Harald ^ad   Buslau, Michael ^ae   Ahmadi Simab, Keihan ^af   Himsel, Andrea ^ah   Juche, Aaron ^e   Koetter, Ina ^ag   Kuhn, Annegret ^h   Sticherling, Michael ^s   Hellmich, Martin ^a   Kuhr, Kathrin ^a   Krieg, Thomas ^a   Ehrchen, Jan ^ai   Sunderkoetter, Cord ^ai   Hunzelmann, Nicolas ^a   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b KRANKENHAUS MERHEIM   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e Immanuel Hospital and Rheumaklinik Berlin Buch   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j JUSTUS LIEBIG UNIVERSITY   (Germany)

^k HELIOS St Elisabeth Klinik   (Germany)

^l ST JOSEF HOSPITAL   (Germany)

^m UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁿ Johanniter Hospital   (Germany)

^o UNIVERSITY HOSPITAL ULM   (Germany)

^p UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^q Department of Rheumatology Clinic of Rheumatology of Aachen   (Germany)

^r UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^s UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^t TUM University Hospital   (Germany)

^u LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^v UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^w UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^x JOHANNES GUTENBERG UNIVERSITY   (Germany)

^y Clinic for Dermatology Hamburg Alstertal   (Germany)

^z HELIOS KLINIKUM WUPPERTAL   (Germany)

^aa Center for Rheumatology Bad Doberan   (Germany)

^ab Center for Rheumatology Acura   (Germany)

^ac UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^ad UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^ae Center for Rheumatology (Rehabilitation)   (Germany)

^af Klinikum Stephansplatz   (Germany)

^ag Asklepios Clinic Altona   (Germany)

^ah GRP Hospital Ruesselheim   (Germany)

^ai UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^aj MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

German network for systemic scleroderma; Real life; Systemic sclerosis; Vasoactive therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; VASOACTIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE REGISTRY; DRUG THERAPY; FEMALE; FINGER ULCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; VASOACTIVE THERAPY; AGE; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; GERMANY; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TREATMENT OUTCOME; VASCULAR DISEASES; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 85011854602     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150382     Document Type: Article

References (35)

1. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev 2007;6:520-3.
2. Galluccio F, Matucci-Cerinic M. Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. Autoimmun Rev 2011;10:241-3.
3. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
4. Walker KM, Pope J; participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails - a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012;42:42-55.
5. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al; EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
6. Walker KM, Pope J; Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011;38:1326-8.
7. Riemekasten G, Sunderkötter C. Vasoactive therapies in systemic sclerosis. Rheumatology 2006;45 Suppl 3:iii49-51.
8. Riemekasten G, Hoffmann U, Sunderkotter C, Weiss N, Kuhn A; angiologisch-dermatologisch-rheumatologische DU-Expertenboard. [Management of digital ulcers in patients with systemic sclerosis]. [Article in German] Dtsch Med Wochenschr 2012;137:34-40.
9. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.
10. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
11. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.
12. Matucci-Cerinic M, Seibold JR. Digital ulcers and outcomes assessment in scleroderma. Rheumatology 2008;47 Suppl 5:v46-7.
13. Hachulla E, Denton CP. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. Eur Respir Rev 2010;19:314-20.
14. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology 2009;48 Suppl 3:iii25-31.
15. Dhillon S. Macitentan: a review of its use in patients with pulmonary arterial hypertension. Drugs 2014;74:1495-507.
16. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology 2009;48 Suppl 3:iii19-24.
17. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
18. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
19. Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J 1998;135:S21-30.
20. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42:2646-55.
21. Whitman HH 3rd, Case DB, Laragh JH, Christian CL, Botstein G, Maricq H, et al. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum 1982;25:241-8.
22. Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69:1475-8.
23. Kumar U, Sankalp G, Sreenivas V, Kaur S, Misra D. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. Rheumatol Int 2013;33:1047-52.
24. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5.
25. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013;72:1696-9.
26. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, et al; Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008;47:1185-92.
27. Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I, et al; German Network for Systemic Scleroderma Centers. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009;11:R30.
28. Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, et al; all participating DNSS centers. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2015;74:730-7.
29. Opitz C, Klein-Weigel PF, Riemekasten G. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa 2011;40:20-30.
30. Pope J, Harding S, Khimdas S, Bonner A, Baron M; Canadian Scleroderma Research Group. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol 2012;39:524-31.
31. Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res 2013;65:1460-71.
32. Romaniello A, Viola G, Salsano F, Rosato E. In systemic sclerosis patients, bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension. Rheumatology 2014;53:570-1.
33. Kane LB, Klings ES. Present and future treatment strategies for pulmonary arterial hypertension: focus on phosphodiesterase-5 inhibitors. Treat Respir Med 2006;5:271-82.
34. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
35. Herrgott I, Riemekasten G, Hunzelmann N, Sunderkötter C. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network. Rheumatol Int 2008;28:1023-9.